Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Zhili Cao"'
Publikováno v:
Current Oncology, Vol 29, Iss 8, Pp 5715-5730 (2022)
Microsatellite instability (MSI), high tumor mutation burden (TMB-H) and programmed cell death 1 ligand 1 (PD-L1) expression are hot biomarkers related to the improvement of immunotherapy response. Two cohorts of non-small-cell lung cancer (NSCLC) we
Externí odkaz:
https://doaj.org/article/290f77c9b1c44ff28a4c7e2f8195174b
Autor:
Zhongxing Bing, Ziqi Jia, Yadong Wang, Jianchao Xue, Lei Cao, Zhili Cao, Peng Liu, Ji Li, Naixin Liang, Shanqing Li
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2130-2133 (2021)
Abstract The treatment of stage IIIB non‐small cell lung cancer (NSCLC) is complicated, the best strategy is chosen individually and surgery is usually not recommended. A 50‐year‐old female was diagnosed with locally advanced lung adenocarcinom
Externí odkaz:
https://doaj.org/article/99432d6287294da7af4b44b793cf30e7
Autor:
Naixin Liang, Zhongxing Bing, Yadong Wang, Xinyu Liu, Chao Guo, Lei Cao, Yuan Xu, Yang Song, Chao Gao, Zhenhuan Tian, Pancheng Wu, Jianchao Xue, Bowen Li, Ziqi Jia, Xiaoying Yang, Yijun Wu, Ruoying Yu, Rui Liu, Xiaoxi Chen, Qiuxiang Ou, Hua Bao, Xue Wu, Zhili Cao, Ji Li, Shanqing Li
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 5, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/1f2475a814ec4241a1426bd29fa299de
Autor:
Yadong Wang, Tiange Wang, Jianchao Xue, Ziqi Jia, Xinyu Liu, Bowen Li, Ji Li, Xiaoguang Li, Weiwei Wang, Zhongxing Bing, Lei Cao, Zhili Cao, Naixin Liang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed
Externí odkaz:
https://doaj.org/article/b234cfa18bad49dabcd082bc8b42e7da
Autor:
Huaxia Yang, Yadong Wang, Ziqi Jia, Yanyu Wang, Xiaoying Yang, Pancheng Wu, Yang Song, Huihui Xu, Dejian Gu, Rongrong Chen, Xuefeng Xia, Zhongxing Bing, Chao Gao, Lei Cao, Shanqing Li, Zhili Cao, Naixin Liang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Lung cancer is the leading cause of cancer-related deaths worldwide, and its occurrence is related to the accumulation of gene mutations and immune escape of the tumor. Sequencing of the T-cell receptor (TCR) repertoire can reveal the immunosurveilla
Externí odkaz:
https://doaj.org/article/c8d620bd8d414dca95047dcd18621c5e
Autor:
Yadong Wang, Ling Peng, Ming Zhao, Yuanyuan Xiong, Jianchao Xue, Bowen Li, Zhicheng Huang, Xinyu Liu, Xiaoying Yang, Yang Song, Zhongxing Bing, Chao Guo, Zhenhuan Tian, Chao Gao, Lei Cao, Zhili Cao, Ji Li, Xu Jiang, Xiaoyan Si, Li Zhang, Xiaoguang Li, Zhibo Zheng, Mengmeng Song, Rongrong Chen, Wan-Teck Lim, Alberto Pavan, Atocha Romero, Naixin Liang, Huaxia Yang, Shanqing Li
Publikováno v:
Translational Lung Cancer Research. 11:1936-1950
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::963ba00bc0727fa47bdc3f5b0ec36ede
https://doi.org/10.21037/tlcr-22-629
https://doi.org/10.21037/tlcr-22-629
Autor:
Pancheng Wu, Cheng Huang, Hongsheng Liu, Jiayue Xu, Xin Guo, Zhongxing Bing, Hao Liu, Huiling Chu, Li Li, Han Han-Zhang, Xingyu Yang, Shuai Fang, Lei Cao, Jianxing Xiang, Yanyu Wang, Yingzhi Qin, Zhihong Zhang, Chenyang Wang, Shanqing Li, Naixin Liang, Yijun Wu, Heng Zhao, Jing Su, Chengju Wu, Yushang Cui, Bingsi Li, Zhili Cao, Ziqi Jia, Feng Xu, Tao Zheng, Fujun Qiu
Publikováno v:
Nature Biomedical Engineering. 5:586-599
The low abundance of circulating tumour DNA (ctDNA) in plasma samples makes the analysis of ctDNA biomarkers for the detection or monitoring of early-stage cancers challenging. Here we show that deep methylation sequencing aided by a machine-learning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::973ce93066881f7be5822d8209420d3e
https://doi.org/10.1038/s41551-021-00746-5
https://doi.org/10.1038/s41551-021-00746-5
Autor:
Ji Li, Zhongxing Bing, Zhili Cao, Jianchao Xue, Ziqi Jia, Yadong Wang, Peng Liu, Naixin Liang, Lei Cao, Shanqing Li
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 14, Pp 2130-2133 (2021)
Thoracic Cancer, Vol 12, Iss 14, Pp 2130-2133 (2021)
The treatment of stage IIIB non‐small cell lung cancer (NSCLC) is complicated, the best strategy is chosen individually and surgery is usually not recommended. A 50‐year‐old female was diagnosed with locally advanced lung adenocarcinoma (stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83b6078966c98db19a894af2e6dfd3ed
http://europepmc.org/articles/PMC8287007
http://europepmc.org/articles/PMC8287007
Background: Lung adenocarcinoma (LUAD) is the most heterogeneous and aggressive among all NSCLC subtypes. This work aimed to determine the predictive ability of DYNLL1 and RAN in LUAD, as well as to explore the role of possible DYNLL1 and Ran molecul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08acdfe7499d6c835d601771ced5e913
https://doi.org/10.21203/rs.3.rs-746416/v1
https://doi.org/10.21203/rs.3.rs-746416/v1
Autor:
Jing Liu, Bing Li, Puyuan Xing, Yang Song, Zhili Cao, Lei Cao, Xinru Mao, Ke Ma, Huaxia Yang, Hao Liu, Yanyu Wang, Lu Zhang, Naixin Liang, Peng Chen, Tengfei Zhang, Zhe Zhang, Zhongxing Bing, Pancheng Wu, Shanqing Li, Yudong Su, Jianxing Xiang, Xiang Long, Yijun Wu
Publikováno v:
Targeted Oncology. 14:159-168
ALK-rearranged non-small cell lung cancer (NSCLC) represents a molecular subgroup with high sensitivity to ALK inhibitors. Crizotinib, a US Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treating ALK-rearranged NSCLC, has s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17a1e70e0b80ebdc1fc87ba5feaea6d0
https://doi.org/10.1007/s11523-019-00631-x
https://doi.org/10.1007/s11523-019-00631-x